Sudeep Pharma Limited, a technology-driven manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition sectors, is set to launch its mainboard IPO worth ₹895 crore, opening on November 21, 2025, and closing on November 25, 2025. The initial public offering consists of a fresh issue of ₹95 crore and an Offer for Sale (OFS) of ₹800 crore. The price band for the issue is fixed between ₹563 and ₹593 per equity share. The unofficial Grey Market Premium (IPO GMP) for Sudeep Pharma is currently a major talking point, signaling strong demand.

Market reports indicate that the IPO GMP is fluctuating between ₹93 and ₹122 per share. When the highest premium of ₹122 is added to the upper end of the issue price band (₹593), the estimated listing price for Sudeep Pharma shares is approximately ₹715. This suggests a potential listing gain of over 20% for investors. This bullish IPO GMP sentiment is underpinned by Sudeep Pharma’s robust business model, which includes a diversified portfolio of over 200 products, a global presence across 100+ countries, and strong relationships with marquee clients like Pfizer and Danone. Proceeds from the fresh issue are planned for capital expenditure, specifically for procuring machinery at its Gujarat facility. The strong IPO GMP and solid fundamentals make this a high-interest IPO for retail and institutional investors.